FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Disclosed is a method of increasing FoxP3+ regulatory T cells in a patient with lupus, comprising administering to patient a therapeutically effective amount of an anti-CD52 antibody. Also disclosed is use of monoclonal anti-CD52 antibody for preparing a drug for increasing number of FoxP3+ regulatory T-cells, as well as a kit comprising said anti-CD52 antibody and a second agent stimulating FoxP3+ regulatory T-cells.
EFFECT: invention enables to relieve lupus symptoms a patient.
29 cl, 25 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INDUCTION OF IMMUNE TOLERANCE USING METHOTREXATE | 2012 |
|
RU2674036C2 |
| METHOD OF OBTAINING POPULATION OF HUMAN CD4+CD25+Foxp3+ T-LYMPHOCYTES ex vivo, DISEASE TREATMENT METHOD | 2008 |
|
RU2391401C2 |
| METHOD OF HUMAN REGULATORY CD4CD25FOXP3T-CELL ENRICHMENT ex vivo | 2010 |
|
RU2437933C1 |
| COMPOSITIONS FOR TREATMENT OF DISSEMINATED SCLEROSIS | 2008 |
|
RU2492234C2 |
| METHOD OF TREATING AUTOIMMUNE DISEASE (VERSIONS) | 2009 |
|
RU2539110C2 |
| COMPOSITIONS CAUSING SPECIFIC RESPONSE OF CYTOTOXIC T-LYMPHOCYTES, INCLUDING LYMPH-ABLATIVE COMPOUND AND MOLECULE WHICH CONTAINS ANTIGEN SEQUENCES AND IS TARGETED AT SPECIALISED ANTIGEN-PRESENTING CELLS | 2007 |
|
RU2448729C2 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
| REDUCED SYSTEMIC LEVELS OR ACTIVITY OF REGULATORY T-CELLS FOR TREATING DISEASE AND CENTRAL NERVOUS SYSTEM INVOLVEMENT | 2017 |
|
RU2815892C1 |
| AGENT FOR DISEASE TREATMENT | 2009 |
|
RU2540018C2 |
| ANTIBODIES AGAINST OX40 AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2562874C1 |
